MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.24 -1.59

Buy Sell

Overview

Share price change

24h

Current

Min

1.21

Max

1.28

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+57.48% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-36M 138M
Previous open	2.83
Previous close	1.24

News Sentiment

By Acuity

50%

161 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2026, 00:00 UTC

Major News Events

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 kwi 2026, 00:00 UTC

Major News Events

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 kwi 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 kwi 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 kwi 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9 kwi 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 kwi 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 kwi 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 kwi 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 kwi 2026, 20:57 UTC

Major News Events

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 kwi 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 kwi 2026, 20:25 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 kwi 2026, 19:30 UTC

Major News Events

How Digital Currencies Have Helped Iran -- WSJ

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

57.48% upside

12 Months Forecast

Average 2 USD 57.48%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

161 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.